RLM - Realm Therapeutics Plc

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.9000
+0.0700 (+2.47%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.8300
Open2.7100
Bid0.0100 x 800
Ask3.0600 x 900
Day's Range2.7000 - 2.9000
52 Week Range1.3500 - 13.0000
Volume24,766
Avg. Volume22,587
Market Cap13.521M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Benzingalast month

    ESSA Pharma, Realm Therapeutics To Merge In $20M Deal

    The acquisition is expected to be completed by mid 2019. Once the acquisition is complete the company will continue to operate as ESSA Pharma, and trade on the Nasdaq and TSX-V Market and operating in the United States as ESSA Pharmaceuticals Corp. The terms of the acquisition value Realm's issued and outstanding shares at approximately $21.5 million, which represents a 5 percent premium over Realm's estimated net cash amount of $20.5 million at the closing of the acquisition.

  • Malvern biopharm firm to shed assets in $10M deal
    American City Business Journals3 months ago

    Malvern biopharm firm to shed assets in $10M deal

    The company began exploring 'strategic options' after a key product failed in midstage clinical testing in September.

  • Our Take On Realm Therapeutics Plc’s (LON:RLM) CEO Salary
    Simply Wall St.6 months ago

    Our Take On Realm Therapeutics Plc’s (LON:RLM) CEO Salary

    Alex Martin became the CEO of Realm Therapeutics Plc (LON:RLM) in 2015. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, Read More...